Mechanism of ETI Therapy on NLRP3 Inflammasome in Cystic Fibrosis
Publisher：Unknown
·Published at: 2025-12-14
Discussion regarding how elexacaftor/tezacaftor/ivacaftor (ETI) therapy functions to downregulate the NLRP3 inflammasome pathway and subsequently reduce pro-inflammatory cytokine production in the context of cystic fibrosis.
Loading...